AI Article Synopsis

  • Folate receptor α (FRα) is a promising target for treating cervical cancer, with high FRα expression found in 72.4% of studied patients, particularly in non-squamous cell carcinomas (non-SCC).
  • The study analyzed samples from 123 cervical cancer patients, assessing FRα and PD-L1 expression, finding a weak correlation between FRα and PD-L1 levels along with CD8-positive cell counts.
  • High FRα expression was linked to worse patient outcomes, especially in those with low PD-L1 expression (CPS <10), suggesting that targeting FRα could be an effective treatment strategy for patients with cervical cancer who exhibit low PD-L1 levels.

Article Abstract

Folate receptor α (FRα) is a cell-surface protein and an attractive target for cancer treatment. We investigated the association between FRα expression and the tumor immune microenvironment in patients with cervical cancer. We examined whole tumor sections of 123 patients with cervical cancer: 67 and 56 sections of squamous cell carcinoma (SCC) and non-SCC, respectively. FRα expression was assessed using immunohistochemical staining with the anti-FRα monoclonal antibody clone 26B3. Programmed death-ligand 1 (PD-L1) expression was assessed using a combined positive score (CPS). The intratumoral CD3 and CD8 cell densities were calculated as the average number of positive cells in five independent areas. FRα-positivity was identified in 72.4% of the patients, and it differed by histology (SCC vs. non-SCC; 55.2% vs. 92.9%, P<0.001). PD-L1 status was positive (CPS ≥1) in 75.6% and was more commonly expressed in patients with SCC (SCC vs. non-SCC; 83.5% vs. 66.1%, P=0.02). FRα expression had a weak correlation with PD-L1 expression (r=-0.22, P<0.001) and CD8-positive cells (r=-0.19, P=0.03). FRα-positivity was more frequently observed in the PD-L1 CPS <10 group than in the PD-L1 CPS ≥10 group (81% vs. 64%, P=0.03). FRα-high was significantly associated with poor prognosis, especially in the PD-L1 CPS ≥10 groups (hazard ratio: 4.10, 95% confidence interval: 1.39-12.06, P=0.01). In conclusion, FRα expression was higher in patients with cervical cancer and PD-L1 CPS <10 than in those with CPS ≥10. Targeting FRα expression may be a potential therapeutic strategy for cervical cancer patients with low or negative PD-L1 expression.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000001051DOI Listing

Publication Analysis

Top Keywords

patients cervical
12
cervical cancer
12
folate receptor
8
expression tumor
8
tumor immune
8
immune microenvironment
8
microenvironment patients
8
frα expression
8
scc non-scc
8
expression assessed
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!